Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Sarepta Therapeutics Inc (NASDAQ: SRPT) was $23.25 for the day, down -0.85% from the previous closing price of $23.45. In other words, the price has decreased by -$0.85 from its previous closing price. On the day, 3.4 million shares were traded. SRPT stock price reached its highest trading level at $23.39 during the session, while it also had its lowest trading level at $22.7883.
Ratios:
Our analysis of SRPT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 1.00.
On July 29, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $37.
JP Morgan Upgraded its Underweight to Neutral on July 29, 2025, while the target price for the stock was maintained at $24.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 13 ’25 when Sarepta Therapeutics, Inc. bought 9,265,312 shares for $19.99 per share.
Nicaise Claude sold 2,491 shares of SRPT for $248,203 on Mar 12 ’25. The Director now owns 27,812 shares after completing the transaction at $99.64 per share. On Mar 12 ’25, another insider, Nicaise Claude, who serves as the Director of the company, bought 2,491 shares for $99.65 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 2433622528 and an Enterprise Value of 2835991552. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.92 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 1.143 whereas that against EBITDA is 70.64.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.53, which has changed by -0.8114202 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $138.81, while it has fallen to a 52-week low of $10.41. The 50-Day Moving Average of the stock is 15.15%, while the 200-Day Moving Average is calculated to be -51.61%.
Shares Statistics:
SRPT traded an average of 7.89M shares per day over the past three months and 3789350 shares per day over the past ten days. A total of 97.71M shares are outstanding, with a floating share count of 92.34M. Insiders hold about 5.50% of the company’s shares, while institutions hold 88.80% stake in the company. Shares short for SRPT as of 1760486400 were 17686193 with a Short Ratio of 2.24, compared to 1757894400 on 20276086. Therefore, it implies a Short% of Shares Outstanding of 17686193 and a Short% of Float of 19.590001.
Earnings Estimates
The company has 12.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.64, with high estimates of $1.41 and low estimates of -$2.05.
Analysts are recommending an EPS of between $3.98 and -$4.66 for the fiscal current year, implying an average EPS of -$2.32. EPS for the following year is $3.18, with 13.0 analysts recommending between $6.3 and $1.35.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 22 analysts. It ranges from a high estimate of $388M to a low estimate of $213.19M. As of. The current estimate, Sarepta Therapeutics Inc’s year-ago sales were $467.17MFor the next quarter, 22 analysts are estimating revenue of $349.38M. There is a high estimate of $487.5M for the next quarter, whereas the lowest estimate is $113.19M.
A total of 22 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $2.19B, while the lowest revenue estimate was $1.68B, resulting in an average revenue estimate of $2.04B. In the same quarter a year ago, actual revenue was $1.9BBased on 21 analysts’ estimates, the company’s revenue will be $1.61B in the next fiscal year. The high estimate is $2.25B and the low estimate is $1.23B.
